Related Experiment Video

Updated: Jul 30, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance

Xiang Cai1, Xi Duan2, Tielong Tang1

  • 1Department of Urology, Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South Road, Sichuan, 637000, Nanchong, China.

BMC Cancer
|May 10, 2023
PubMed
Abstract

Insights

JMJD2A promotes docetaxel resistance in prostate cancer by altering cytoskeleton remodeling via the miR-34a/STMN1/β3-Tubulin pathway, impacting cell proliferation and apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Castration-resistant prostate cancer (CRPC) often develops resistance to docetaxel chemotherapy.
  • The underlying mechanisms of docetaxel resistance, particularly involving cytoskeleton remodeling, require further investigation.

Purpose of the Study:

  • To elucidate the role of JMJD2A in regulating cytoskeleton remodeling in docetaxel-resistant CRPC.
  • To identify the molecular pathway, including microRNA and protein interactions, through which JMJD2A exerts its effects.

Main Methods:

  • Analysis of JMJD2A, miR-34a, and cytoskeleton-related protein expression in CRPC patient tissues.
  • In vitro studies involving knockdown of JMJD2A, STMN1, and TUBB3 in CRPC cell lines.
  • Assessment of cell viability, apoptosis, and molecular interactions using qPCR, western blot, dual-luciferase reporter, and co-immunoprecipitation assays.

Main Results:

  • Higher JMJD2A and STMN1 expression, with lower miR-34a and β3-Tubulin, observed in docetaxel-resistant CRPC.
  • JMJD2A regulates cytoskeletal remodeling via the miR-34a/STMN1/β3-Tubulin axis.
  • miR-34a overexpression led to decreased STMN1, increased β3-Tubulin, microtubule disruption, reduced proliferation, G0/G1 cell cycle arrest, and enhanced apoptosis.

Conclusions:

  • JMJD2A promotes docetaxel resistance in prostate cancer.
  • The miR-34a/STMN1/β3-Tubulin axis is a key mediator of JMJD2A-induced cytoskeleton remodeling and chemoresistance.
  • Targeting JMJD2A or modulating this axis may offer therapeutic strategies for overcoming docetaxel resistance in CRPC.
Keywords:
Castration-resistant prostate cancerDocetaxel resistanceJMJD2APDX animal modelmiR-34a/STMN1/β3-Tubulin

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K